Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Harvard Business School
Medtronic
Fuji
Fish and Richardson
Johnson and Johnson

Generated: July 21, 2019

DrugPatentWatch Database Preview

Patent: 7,888,489

Try a free trialSee Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,888,489
Title:Method for producing a compound of interest in a filamentous fungal cell
Abstract: The invention relates to a nucleotide sequence comprising; a synonymous nucleotide coding sequence with optimized codon frequency such that a native codon has been exchanged with a synonymous codon, the synonymous codon encoding the same amino acid as the native codon and having a higher frequency in codon usage as defined in Table 1 than the native codon; and optionally the nucleotide sequence comprises control sequences such as; one translational termination sequence orientated in 5\' towards 3\' direction selected from the following list of sequences; TAAG, TAGA and TAAA, preferably TAAA, and/or one translational initiator coding sequence orientated in 5\' towards 3\' direction selected from the following list of sequences; gctnccyyc (SEQ ID NO:20), using ambiguity codes for nucleotides; v (A/C/G); n (A/C/G/T), preferably 5\'-GCT TCC TTC-3\' (SEQ ID NO:21). The invention further relates to a consensus translational initiator sequence; 5\'-mwChkyCAmv-3\' (SEQ ID NO:16), preferably the translational initiator sequence is selected from the list consisting of; 5\'-mwChkyCAAA-3\' (SEQ ID NO:17), 5\'-mwChkyCACA-3\' (SEQ ID NO:18), and 5\'-mwChkyCAAG-3\' (SEQ ID NO:19).
Inventor(s): Roubos; Johannes Andries (Pijnacker, NL), Donkers; Serge Petrus (Hellevoetsluis, NL), Stam; Hein (Huizen, NL), Peij; Noel Nicolaas Maria Elisabeth Van (Delft, NL)
Assignee: DSM IP Assets B.V. (Heerlen, NL)
Application Number:11/795,824
Patent Claims:see list of patent claims

Details for Patent 7,888,489

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04 ➤ Sign Up DSM IP Assets B.V. (Heerlen, NL) ➤ Sign Up RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04 ➤ Sign Up DSM IP Assets B.V. (Heerlen, NL) ➤ Sign Up RX search
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04 ➤ Sign Up DSM IP Assets B.V. (Heerlen, NL) ➤ Sign Up RX search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Johnson and Johnson
US Army
Chinese Patent Office
Accenture
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.